4 results about "Early stage disease" patented technology

A technique for expansion microscopy (ExM) utilizing anchorable derivatives of hematoxylin and eosin (H&E) stained tissue specimens within tissue samples, in order to achieve high resolution detection of biomolecules with precise morphological features of cells and nuclei, which in turn, allows for effective for accurate early stage disease diagnosis including various cancers. Staining with H&E employs anchorable derivatives that can be cross-linked into the ExM hydrogel matrix.

The present invention relates to the technical field of prevention and control of aquatic animal diseases, and specifically relates to a nanocomposite for a nervous necrosis virus, a preparation method therefor, and the use thereof. Provided in the present invention is a nanocomposite consisting of poly(lactic-co-glycolic acid), polyethyleneimine and a siRNA. Also provided in the present invention are a preparation method for the nanocomposite and the use thereof in the preparation of a drug for improving the survival rate of fish eggs infected with a nervous necrosis virus. The present invention constructs a vector for a capsid protein of the nervous necrosis virus by means of simulating the nervous necrosis virus and expresses same in cells, and screens out a siRNA that can effectively inhibit the expression of the viral capsid protein, thus constructing the nanocomposite for the nervous necrosis virus. The nanocomposite can block NNVs at the embryonic phase (fertilized eggs), thereby improving the survival rate of fish fry, and further opening up new possibilities for the treatment of early stage diseases in fish fry. The method is innovative in the field of artificial breeding of aquatic animals and provides new ideas for virus prevention and control in the field of aquaculture.

The invention discloses an Alzheimer's disease risk prediction model and a construction method and application thereof. In the invention, a key factor combination of the Alzheimer's disease, which is composed of FZD6, GRIN2A, TUBA8, RYR3, NDUFS3 and TNF in human plasma, is found for the first time, and an early prediction model which can be used for predicting the incidence probability of the Alzheimer's disease is constructed and processed in combination with a machine learning algorithm, so that the early prediction capability of the Alzheimer's disease is improved; powerful technical support is provided for prevention and early treatment of the Alzheimer's disease.

The invention relates to a gene expression based biomarker that is predictive of patient clinical need for treatment that includes a PD-1 antagonist, wherein the gene expression based biomarker comprises five or more genes selected from the genes listed in Table 1 or Table 2 disclosed herein. More specifically, a negative level of a gene expression based biomarker wherein the biomarker comprises five or more genes selected from the genes listed in Table 1 or a positive level of a gene expression based biomarker wherein the biomarker comprises 5 or more genes selected from the genes listed in Table 2 is associated with favorable prognosis in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as positive for a gene expression based biomarker of the invention. The disclosure also provides methods and kits for testing tumor samples for the biomarkers.